Juan Camilo Arjona Ferreira - Aug 27, 2021 Form 4 Insider Report for Myovant Sciences Ltd. (MYOV)

Role
Chief Medical Officer
Signature
/s/ Matthew Lang, Attorney-in-fact
Stock symbol
MYOV
Transactions as of
Aug 27, 2021
Transactions value $
-$386,551
Form type
4
Date filed
8/31/2021, 05:23 PM
Previous filing
Jul 9, 2021
Next filing
Sep 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYOV Common Shares Sale -$44.9K -1.98K -1.14% $22.69 171K Aug 27, 2021 Direct F1
transaction MYOV Common Shares Options Exercise $163K +21K +12.26% $7.78 192K Aug 30, 2021 Direct
transaction MYOV Common Shares Sale -$505K -21K -10.92% $24.05 171K Aug 30, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYOV Stock Option (Right to Buy) Options Exercise $0 -21K -11.22% $0.00 166K Aug 30, 2021 Common Shares 21K $7.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
F2 Shares sold pursuant to a 10b5-1 trading plan.
F3 The shares were sold at prices ranging from $24.00 to $24.20. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.